Pharvaris (NASDAQ: PHVS) CTO reports option grants and share holdings
Rhea-AI Filing Summary
Pharvaris N.V. executive Stefan Andreas Abele, Chief Technical Ops Officer, reports his initial equity holdings. He holds several stock option awards over common shares, including options exercisable at $28.0000, $16.0500, $22.3100 and $16.4000, with expiration dates between November 15, 2033 and March 3, 2036. These options cover 60,000, 60,000, 40,000 and 89,500 underlying common shares, respectively. He also reports direct ownership of 43,942 shares of common stock as of March 18, 2026, which includes restricted stock units granted under the company’s equity plan that vest over time according to the schedules described in the footnotes.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Abele Stefan Andreas
Role
Chief Technical Ops Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 249,500 shares (Direct);
Common Stock — 43,942 shares (Direct)
Footnotes (5)
- F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% vested March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -6,849 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.
- F2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F5. 25% of the option vested on November 15, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Pharvaris (PHVS) Form 3 for Stefan Andreas Abele report?
The Form 3 reports initial equity holdings for Chief Technical Ops Officer Stefan Andreas Abele, including stock options over multiple blocks of Pharvaris common shares and direct ownership of 43,942 common shares as of March 18, 2026, with detailed vesting terms in the footnotes.
What direct common stock holdings does Stefan Andreas Abele report in Pharvaris (PHVS)?
Abele reports direct ownership of 43,942 common shares of Pharvaris N.V. as of March 18, 2026. According to the footnotes, this figure includes restricted stock units granted under the company’s equity plan that settle in common stock and vest over time.
How do Stefan Andreas Abele’s Pharvaris (PHVS) stock options vest?
The options generally vest 25% on a key date, then monthly. Each grant specifies that 25% of the option vests on its initial vesting date, such as March 3, 2027 or March 12, 2026, with the remaining shares vesting in 1/48 monthly installments thereafter.
What are the key details of Abele’s restricted stock units in Pharvaris (PHVS)?
The footnotes describe several RSU grants and vesting schedules, including awards granted on March 3, 2026, March 12, 2025 and April 11, 2024. Each award vests 25% on the first anniversary grant date, with the remaining RSUs vesting monthly thereafter and settling in common stock.